KROS: Keros Therapeutics, Inc. Stock

by  •  • Comments Off on KROS: Keros Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,954.51
Enterprise Value ($M) 1,623.37
Book Value ($M) 332.21
Book Value / Share 9.21
Price / Book 5.88
NCAV ($M) 309.48
NCAV / Share 8.58
Price / NCAV 6.32

Profitability (mra)
Return on Invested Capital (ROIC) -0.44
Return on Assets (ROA) -0.40
Return on Equity (ROE) -0.43

Liquidity (mrq)
Quick Ratio 14.25
Current Ratio 14.25

Balance Sheet (mrq) ($M)
Current Assets 347.29
Assets 370.02
Liabilities 37.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.15
Operating Income -169.94
Net Income -152.99

Cash Flow Statement (mra) ($M)
Cash From Operations -124.51
Cash from Investing -2.46
Cash from Financing 178.96

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Alkeon Capital Management Llc 5.00 7.65
02-09 13G/A Fmr Llc 12.93 5.30
01-26 13G/A BlackRock Inc. 6.80 24.32
12-13 13D/A Orbimed Advisors Llc 4.20 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 42,269 228,511 18.50
2024-04-25 49,778 261,556 19.03
2024-04-24 55,417 110,889 49.98
2024-04-23 51,324 203,299 25.25

(click for more detail)

Similar Companies
JANX – Janux Therapeutics, Inc. KALV – KalVista Pharmaceuticals, Inc.
KOD – Kodiak Sciences Inc. KYMR – Kymera Therapeutics, Inc.
LBPH – Longboard Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io